Ann: Appendix 4C - quarterly, page-5

The first chart is cumulative sales, unfortunately it's not a 'snapshot' of rising sales in each quarter.
IMO, it's a little cheeky to chart it in this way as it makes is hard to see exactly what the sales are in each quarter.
I don't actually think that sales of Nanabis are 'up' in either of the last 2 quarters or they would still be charting it the way the did in the January 4C (see below).




Also, revenue is down slightly. In the December 4C it was 1.64, April 4C is was 1.35, this 4C 1.42. Supply chain issues?
The cash burn is down which is great, but I suspect that is principally about the Nanabis & NRGBiotic trials being completed.

In general I do like this company but I don't feel like it's got much momentum in the market - the story isn't really out there for investors to sink their teeth into. Sean did mention this in the recent webinar so hopefully we'll hear more from them.

DYOR - GLAH